NICE u-turn recommends some access to Takeda’s Adcetris

28th April 2017 Uncategorised 0

It is now looking likely that some patients with relapsed/refractory (R/R) Hodgkin lymphoma will be able to get routine access to Takeda’s Adcetris on the NHS after a major u-turn by cost regulators.

More: NICE u-turn recommends some access to Takeda’s Adcetris
Source: News